Embera NeuroTherapeutics
Embera NeuroTherapeutics is a development-stage pharmaceutical company developing treatments for smoking cessation and other addictions.
About Embera NeuroTherapeutics
Embera NeuroTherapeutics is a development stage pharmaceutical company focused on developing treatments for smoking cessation and other addictions, for which there are a limited range of effective drug therapies or have no approved treatments. Embera is developing a novel addiction treatment (EMB-001) that targets specific and complementary brain functions that drive the craving and relapse associated with these disorders, an approach based on breakthrough discoveries of the scientific founder.
Company Facts
- Headquarters
- Sudbury
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- early_stage_venture
- Total Funding
- $28,405,300
- Last Funding Type
- series_a
- Last Funding Date
- 2021-02-12
- Website
- emberaneuro.com
Industries & Categories
Addiction Treatment, Biotechnology, Medical Device, Therapeutics
Social Links
Canonical: https://fsome.com/organization/embera-neurotherapeutics-95813 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.